XBP1 and acute lymphoblastic leukemia: XBP1 upregulation predicted a poor response to therapy and shorter survival of patients with aggressive diffuse large B-cell and plasmablastic lymphomas [77], acute lymphoblastic leukemia (ALL) [78], aggressive luminal B and ER+ breast cancers [79,80], and prostate cancer [81].